When the Association of University Technology Managers released its 2005 US licensing survey summary last week, Atlanta-based Emory University ranked first among the 228 responding institutions with approximately $586 million in licensing revenue for fiscal years 2003 to 2005.
 
But a closer look at the data reveals that about 90 percent of Emory’s licensing income from that period – or $525 million – stemmed from a one-time payment from commercial partners for rights to Emtriva, an Emory-developed HIV/AIDS drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.